Elevance Health, Inc. operates a health benefits and healthcare services platform built around affiliated health plans and the Carelon services business. Recurring company news covers Health Benefits results, premium yields, medical-cost trends, Medicaid, Medicare Advantage and employer group membership, and Carelon activity in pharmacy services, behavioral health, value-based care, care delivery, clinical, home health and complex care solutions.
Company updates also address small and midsize employer benefit offerings such as Balanced Funding and MEWAs, primary-care recognition and value-based provider programs, partnerships tied to family and community health, annual and quarterly financial guidance, and leadership changes across Health Benefits and Carelon.
Elevance Health (NYSE: ELV) and the National Diaper Bank Network launched a 12-month national pilot to expand diaper access and study effects on maternal and child health. The program will distribute free diapers to up to 75 families per month at 10 Welcome Rooms, reaching as many as 9,000 families in 2026.
Sites span Bakersfield and Los Angeles, CA; Hialeah, FL; Columbia, MO; Lakewood, NJ; Columbus and Toledo, OH; Houston, TX; and two Washington, D.C. locations. NDBN will evaluate caregiver stress, preventive care access, financial strain, and links to family support services.
Elevance Health (NYSE: ELV) announced management changes to simplify decision-making and strengthen execution across Carelon and Health Benefits. Mark Kaye will expand CFO responsibilities to include oversight of Carelon. Felicia Norwood will lead a consolidated Health Benefits organization. Peter D. Haytaian will transition from President of Carelon effective May 4, 2026, and serve as Special Advisor through December 31, 2026.
The company said Carelon’s operating priorities and client commitments remain unchanged while the consolidation aims to improve coordination across Commercial and Government health benefits.
Elevance Health (NYSE: ELV) reported 4Q25 operating revenue of $49.3B and FY25 revenue of $197.6B. 4Q25 diluted GAAP EPS was $2.47 and adjusted EPS was $3.33; FY25 diluted GAAP EPS was $25.21 and adjusted EPS $30.29. The company returned $4.1B to shareholders in 2025 and announced FY26 guidance of at least $22.30 GAAP EPS and $25.50 adjusted EPS.
Revenue growth was driven by premium yields, acquisitions, and Medicare Advantage membership growth; benefit expense ratio rose to 93.5% in 4Q25. Carelon revenue increased 27% in 4Q25 to $18.7B.
Elevance Health (NYSE: ELV) will release its fourth quarter and full year 2025 financial results on January 28, 2026 at 6:00 a.m. EST. Management will discuss results and outlook on a conference call at 8:30 a.m. EST the same day. The call requires joining at least 15 minutes early and offers domestic and international dial-in numbers plus replay lines available from 11:30 a.m. EST on January 28, 2026 through February 27, 2026. A live webcast and webcast replay will be available via the company’s Investors page at elevancehealth.com.
Elevance Health (NYSE:ELV) outlines how affiliated health plans are evolving to a whole-health model that integrates physical, behavioral and social needs to simplify care and improve outcomes.
The company highlights expanded access to doula care, community pharmacy programs across 500+ pharmacies, benefits for nutritious food, OTC medications and transportation, and digital access via the Sydney app. Elevance notes person-centered LTSS designations across 12 states and describes care managers who coordinate biopsies, community supports and services for members.
The release emphasizes data-driven care coordination, community partnerships, and personalized member support as drivers of improved affordability, quality and confidence in care navigation.
Elevance Health (NYSE: ELV) received multiple credit rating actions from AM Best on December 12, 2025: core BCBS-branded subsidiaries had their Financial Strength Rating affirmed at A (Excellent) and Long-Term ICRs affirmed at a+, while Wellpoint Life and Wellpoint West Virginia were upgraded to A / a+. Granular Insurance was upgraded to A / a (removed from review).
AM Best cited a very strong balance sheet (BCAR), consistent capital and surplus growth, access to a combined $5 billion revolver/commercial paper facility, and sound liquidity; it noted financial leverage at Elevance rose to ~42% but is expected to decline toward 40% by year-end 2025.
Elevance Health (NYSE: ELV) appointed Amy Schulman as an independent director, effective January 12, 2026. Schulman will join the Audit and Finance Committees and brings experience in healthcare innovation, regulatory strategy, and governance.
She is Managing Partner at Polaris Partners (managing $4 billion), Chair of the board at Alnylam Pharmaceuticals, and a Senior Lecturer at Harvard Business School. The board said the appointment supports its ongoing board refreshment and long-term shareholder value objectives.
Elevance Health (NYSE: ELV) announced on December 5, 2025 an expansion of its Virtual Assistant, a conversational digital experience available via the Sydney Health app and Elevance Health–affiliated health plan websites.
The Virtual Assistant provides personalized benefit explanations, in-network provider lists, and cost estimates in seconds, supports Spanish translation, and integrates with the Find Care platform. Early pilot results showed nearly 9 out of 10 users found answers using the tool. It is available now to approximately 22 million commercial plan members, with expansion to Medicare members planned for 2026. Availability may vary and is subject to state-specific approvals.
Elevance Health (NYSE: ELV) on November 24, 2025 outlined how it is using technology and personalized service to simplify access, build trust, and improve member loyalty.
The company described digital tools (mobile chat, AI-enabled identity/issue resolution), care managers and a “My Health Advocate” model in affiliated Medicare plans that match members with the same advocate for continuity. Programs cited include concierge care for conditions such as Crohn’s disease, cancer, behavioral health, and Type 2 diabetes. The company emphasized data protection, 24/7 convenience, and shifting from administrative insurer to lifetime health partner.
Elevance Health (NYSE: ELV) reported 3Q 2025 results with operating revenue $50.1B (up 12% vs. 3Q24) and diluted EPS $5.32 (adjusted $6.03). The company reaffirmed FY2025 guidance for a ~90.0% benefit expense ratio and adjusted diluted EPS ~ $30.00. Segment trends included Health Benefits revenue $42.2B and Carelon revenue $18.3B (up 33% YoY). Benefit expense ratio rose to 91.3% (+180 bps). Year-to-date capital returned totaled $3.3B; Q3 buybacks were $875M and the board has $7.2B repurchase authorization remaining.
Cash and investments at parent were about $2.6B as of Sept 30, 2025.